Quantres Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Quantres Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-8,800	Closed	-$857K	–	246
2018 Q4	$857K	Buy	+8,800	New	+$1.04M	0.53%	56
2018 Q3	–	Sell	-10,300	Closed	-$1.28M	–	300
2018 Q2	$1.28M	Sell	10,300 -15,000	-59%	-$1.75M	0.74%	42
2018 Q1	$2.82M	Buy	+25,300	New	+$3.02M	1.71%	12
2017 Q3	–	Sell	-9,500	Closed	-$1.16M	–	257
2017 Q2	$1.16M	Buy	+9,500	New	+$1.11M	0.75%	42
2016 Q4	–	Sell	-6,600	Closed	-$809K	–	246
2016 Q3	$809K	Sell	6,600 -4,600	-41%	-$592K	0.5%	72
2016 Q2	$1.31M	Buy	+11,200	New	+$1.59M	0.81%	39
2015 Q2	–	Sell	-4,500	Closed	-$780K	–	222
2015 Q1	$780K	Buy	4,500 +1,900	+73%	+$344K	0.78%	37
2014 Q4	$481K	Buy	+2,600	New	+$482K	0.47%	71
2014 Q3	–	Sell	-6,500	Closed	-$1.02M	–	232
2014 Q2	$1.02M	Buy	+6,500	New	+$1.03M	1.12%	25

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Quantres Asset Management's ALXN Position: Q1 2019 in Review

Quantres Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 8,800 shares — an estimated $857K sold.

Quantres Asset Management first reported a position in ALXN in Q2 2014 and held it in 9 quarters. The position peaked at $2.82M in Q1 2018. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Quantres Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Quantres Asset Management sold 8,800 Alexion Pharmaceuticals shares in Q1 2019, an estimated $857K.
Quantres Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 9 quarters.
Quantres Asset Management's Alexion Pharmaceuticals position peaked at $2.82M in Q1 2018.
612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Quantres Asset Management's 13F filing for Q1 2019, filed 12 Apr 2019.